About Cara Therapeutics (NASDAQ:CARA)
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from uremic pruritus. The company is also developing Oral KORSUVA (CR845/difelikefalin) that has completed Phase I clinical trial to treat uremic pruritus; and in Phase I clinical trial to treat pruritus chronic kidney disease, as well as in Phase I clinical trial for treating pruritus chronic liver disease. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute post-operative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CARA
CUSIPN/A
Phone203-406-3700
Debt
Debt-to-Equity RatioN/A
Current Ratio11.18%
Quick Ratio11.18%
Price-To-Earnings
Trailing P/E Ratio-6.63
Forward P/E Ratio-6.30
P/E GrowthN/A
Sales & Book Value
Annual Sales$910,000.00
Price / Sales443.29
Cash FlowN/A
Price / CashN/A
Book Value$2.66 per share
Price / Book4.64
Profitability
EPS (Most Recent Fiscal Year)($1.86)
Net Income$-58,120,000.00
Net MarginsN/A
Return on Equity-71.69%
Return on Assets-63.47%
Miscellaneous
Employees37
Outstanding Shares32,690,000
Cara Therapeutics (NASDAQ:CARA) Frequently Asked Questions
What is Cara Therapeutics' stock symbol?
Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."
How were Cara Therapeutics' earnings last quarter?
Cara Therapeutics (NASDAQ:CARA) issued its earnings results on Thursday, March, 15th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.39) by $0.04. During the same period in the previous year, the company posted ($0.81) EPS. View Cara Therapeutics' Earnings History.
What price target have analysts set for CARA?
13 brokers have issued 12-month target prices for Cara Therapeutics' shares. Their predictions range from $17.00 to $31.50. On average, they anticipate Cara Therapeutics' stock price to reach $25.4643 in the next year. View Analyst Ratings for Cara Therapeutics.
What are Wall Street analysts saying about Cara Therapeutics stock?
Here are some recent quotes from research analysts about Cara Therapeutics stock:
- 1. According to Zacks Investment Research, "Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. " (3/21/2018)
- 2. Needham & Company LLC analysts commented, "Cara announced outcome of planned CR845 Phase 2/3 post-surgical pain trial interim power assessment today. We spoke w/ mgmt for an update. No changes will be made to current randomization ratio across the 3 arms (1:1:1 placebo, 0.5 ug/kg, 1.0ug/kg), however target enrollment will be increased from 125/ arm to 150/ arm. Other pre-specified options were ending trial early due to low probability of success or shifting enrollment to one optimal dose. We view outcome favorably, noting that the two dose arms were evaluated independently by Data Monitoring Cmtee. Implication is that both low and high dose CR845 have potential for statistically significant effect in view of DMC. We had been concerned that low and possibly high dose evaluated in this trial may not be sufficiently high for efficacy. Mgmt guided for completing enrollment for final analysis by YE17. Separately, top-line results from CR845 Phase 2b trial in Osteoarthritis are expected later this month. We are favorably inclined based on encouraging trends in an 80-pt 2wk Phase 2a trial, but acknowledge risks tied to absence of placebo arm." (6/21/2017)
- 3. HC Wainwright analysts commented, "CR845 as safe as placebo in respiratory safety Phase 1. Cara announced positive data this morning from a 15-patient Phase 1 trial in healthy volunteers designed to formally test for IV ‘845’s impact on respiratory drive, as respiratory depression remains one of the more severe, and potentially life-threatening, side effects of mu opioids, which ‘845 is not. The trial was a three-way crossover design utilizing the expected therapeutic dose of 1.0 ug/kg, as well as a 5.0 ug/kg supratherapeutic dose to test the upper bounds for safety. Patient respiratory drive was measured via end-tidal CO2 (ETCO2), oxygen saturation (SpO2), and respiratory rate, with primary endpoints focused on the former two. ETCO2 ranged from 36.1 to 37.8 mmHg prior to dosing, and remained well below the endpoint threshold of a 10mmHg sustained increase in ETCO2, with values of 38.1, 38.1, and 38.3 mmHg for the placebo, 1.0 ug/kg, and 5.0 ug/kg doses, respectively, one hour after administration. Both doses of ‘845 also hit on the SpO2 primary endpoint (needed to show SpO2 which did not consistently fall below 92%), with pre-treatment levels ranging from 98.3% to 98.9%, finishing an hour later at 97.8%, 98.2%, and 97.9% for the placebo,1.0 ug/kg, and 5.0 ug/kg doses, respectively. While these two primary endpoints only measured through an hour after treatment, no significant differences were seen on all three measures of respiratory drive throughout the entire 4-hour observation period of the study." (4/24/2017)
- 4. Cantor Fitzgerald analysts commented, "The Phase 1 safety trial of IV CR845 showed no significant differences in respiratory drive vs. placebo at super-therapeutic dosing levels." (4/24/2017)
Who are some of Cara Therapeutics' key competitors?
Some companies that are related to Cara Therapeutics include Deciphera Pharmaceuticals (DCPH), Urogen Pharma (URGN), CymaBay Therapeutics (CBAY), OptiNose (OPTN), Vanda Pharmaceuticals (VNDA), Adamas Pharmaceuticals (ADMS), GlycoMimetics (GLYC), Karyopharm Therapeutics (KPTI), NuCana (NCNA), Omeros (OMER), ANI Pharmaceuticals (ANIP), Dova Pharmaceuticals (DOVA), AMAG Pharmaceuticals (AMAG), Rocket Pharmaceuticals (RCKT), Endocyte (ECYT), Lannett (LCI), Reata Pharmaceuticals (RETA) and BeyondSpring (BYSI).
Who are Cara Therapeutics' key executives?
Cara Therapeutics' management team includes the folowing people:
- Dr. Derek T. Chalmers, Co-Founder, Pres, CEO & Director (Age 54)
- Dr. Frédérique Menzaghi Ph.D., Sr. VP of R&D (Age 52)
- Dr. Joseph Stauffer D.O., M.B.A., Chief Medical Officer (Age 52)
- Dr. Michael E. Lewis Ph.D., Co-Founder and Chief Scientific Advisor (Age 66)
- Dr. Mani Mohindru, Chief Financial Officer (Age 46)
Has Cara Therapeutics been receiving favorable news coverage?
Media stories about CARA stock have trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Cara Therapeutics earned a coverage optimism score of 0.18 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 47.07 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Cara Therapeutics?
Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cara Therapeutics' stock price today?
One share of CARA stock can currently be purchased for approximately $12.34.
How big of a company is Cara Therapeutics?
Cara Therapeutics has a market capitalization of $403.40 million and generates $910,000.00 in revenue each year. The biopharmaceutical company earns $-58,120,000.00 in net income (profit) each year or ($1.86) on an earnings per share basis. Cara Therapeutics employs 37 workers across the globe.
How can I contact Cara Therapeutics?
Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at 203-406-3700.
MarketBeat Community Rating for Cara Therapeutics (CARA)
MarketBeat's community ratings are surveys of what our community members think about Cara Therapeutics and other stocks. Vote "Outperform" if you believe CARA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CARA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cara Therapeutics (NASDAQ:CARA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
13 Wall Street analysts have issued ratings and price targets for Cara Therapeutics in the last 12 months. Their average twelve-month price target is $25.4643, suggesting that the stock has a possible upside of 106.36%. The high price target for CARA is $31.50 and the low price target for CARA is $17.00. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.85 | 2.85 | 2.77 | 2.82 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $25.4643 | $25.4643 | $26.0357 | $26.6250 |
| Price Target Upside: | 106.36% upside | 106.69% upside | 109.29% upside | 106.88% upside |
Cara Therapeutics (NASDAQ:CARA) Consensus Price Target History
Cara Therapeutics (NASDAQ:CARA) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Cara Therapeutics (NASDAQ:CARA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Cara Therapeutics (NASDAQ CARA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.70%
Institutional Ownership Percentage: 52.75%
Cara Therapeutics (NASDAQ CARA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/16/2018 | Derek T Chalmers | CEO | Sell | 5,400 | $15.00 | $81,000.00 | 1,071,392 |  |
| 2/15/2018 | Frederique Ph.D. Menzaghi | SVP | Sell | 3,000 | $15.02 | $45,060.00 | 119,000 | |
| 1/24/2018 | Derek T Chalmers | CEO | Sell | 12,500 | $15.00 | $187,500.00 | 1,073,792 | |
| 1/24/2018 | Frederique Ph.D. Menzaghi | SVP | Sell | 15,000 | $15.00 | $225,000.00 | 122,000 | |
| 11/1/2017 | Derek T Chalmers | CEO | Sell | 16,000 | $12.66 | $202,560.00 | 1,066,292 | |
| 7/14/2017 | Derek T Chalmers | CEO | Sell | 25,000 | $15.05 | $376,250.00 | 1,107,292 | |
| 7/14/2017 | Frederique Ph.D. Menzaghi | VP | Sell | 3,000 | $15.00 | $45,000.00 | 120,000 | |
| 6/29/2017 | Dean Slagel | Director | Sell | 250,000 | $25.87 | $6,467,500.00 | | |
| 3/31/2017 | Ventures Vi Lp Rho | Major Shareholder | Buy | 500,000 | $18.19 | $9,095,000.00 | | |
| 4/20/2016 | Frederique Ph.D. Menzaghi | VP | Sell | 6,000 | $9.00 | $54,000.00 | 123,000 | |
| 3/17/2016 | Ventures Vi Lp Rho | Major Shareholder | Buy | 400,000 | $4.87 | $1,948,000.00 | | |
| 2/3/2016 | Frederique Ph.D. Menzaghi | VP | Sell | 6,000 | $9.04 | $54,240.00 | 129,000 | |
| 1/26/2016 | Michael E Lewis | Insider | Sell | 7,262 | $10.93 | $79,373.66 | 314,988 | |
| 1/6/2016 | Derek T Chalmers | CEO | Sell | 12,500 | $17.22 | $215,250.00 | 1,087,292 | |
| 12/1/2015 | Frederique Ph.D. Menzaghi | VP | Sell | 6,000 | $16.21 | $97,260.00 | 141,000 | |
| 11/2/2015 | Frederique Ph.D. Menzaghi | VP | Sell | 6,000 | $14.26 | $85,560.00 | 147,000 | |
| 10/1/2015 | Frederique Ph.D. Menzaghi | VP | Sell | 6,000 | $13.95 | $83,700.00 | 153,000 | |
| 9/1/2015 | Frederique Ph.D. Menzaghi | VP | Sell | 7,000 | $18.63 | $130,410.00 | 159,000 | |
| 8/18/2015 | Josef Schoell | CFO | Buy | 3,000 | $22.10 | $66,300.00 | 28,000 | |
| 6/1/2015 | Michael E Lewis | Insider | Sell | 7,262 | $9.50 | $68,989.00 | | |
| 5/19/2015 | Dean Slagel | Director | Sell | 188,811 | $10.02 | $1,891,886.22 | | |
| 4/1/2015 | Michael E Lewis | Insider | Sell | 7,262 | $9.90 | $71,893.80 | | |
| 3/2/2015 | Michael E Lewis | Insider | Sell | 7,262 | $10.11 | $73,418.82 | | |
| 2/2/2015 | Michael E Lewis | Insider | Sell | 7,262 | $10.60 | $76,977.20 | | |
| 2/5/2014 | Ventures Vi Lp Rho | Major Shareholder | Buy | 225,818 | $11.00 | $2,483,998.00 | | |
(Data available from 1/1/2013 forward)
Cara Therapeutics (NASDAQ CARA) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Cara Therapeutics (CARA) Stock Rating Lowered by Vetr
www.americanbankingnews.com - April 20 at 5:18 PM |
| Vetr Upgrades Cara Therapeutics (CARA) to "Buy"
www.americanbankingnews.com - April 20 at 11:19 AM |
| Vetr Upgrades Cara Therapeutics (CARA) to "Strong-Buy"
www.americanbankingnews.com - April 20 at 10:45 AM |
| Cara Therapeutics (CARA) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 19 at 5:55 AM |
| Cara Therapeutics (CARA) Downgraded by BidaskClub
www.americanbankingnews.com - April 15 at 12:04 AM |
 | Cara Therapeutics Announces Participation in 2018 Spring Clinical Meetings of the National Kidney Foundation
finance.yahoo.com - April 10 at 3:01 PM |
| Needham & Company LLC Reiterates "Buy" Rating for Cara Therapeutics (CARA)
www.americanbankingnews.com - April 7 at 11:00 PM |
 | Here's Why Cara Therapeutics Slipped 11.4% in March
www.msn.com - April 6 at 3:14 PM |
| Here's Why Cara Therapeutics Slipped 11.4% in March
finance.yahoo.com - April 6 at 3:14 PM |
| Should You Be Concerned About Cara Therapeutics Inc’s (NASDAQ:CARA) Earnings Growth?
finance.yahoo.com - April 4 at 4:43 PM |
| Cara Therapeutics (CARA) Price Target Cut to $24.00 by Analysts at CIBC
www.americanbankingnews.com - April 1 at 2:38 PM |
| Cara Therapeutics (CARA) Price Target Raised to $26.00
www.americanbankingnews.com - April 1 at 2:38 PM |
| Cara Therapeutics (CARA) Rating Reiterated by BMO Capital Markets
www.americanbankingnews.com - April 1 at 2:38 PM |
| Don't Get Greedy With Cara Therapeutics, Inc. Stock
www.msn.com - March 28 at 3:03 PM |
| Don't Get Greedy With Cara Therapeutics, Inc. Stock
finance.yahoo.com - March 28 at 3:03 PM |
| Cara Therapeutics Inc (CARA) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - March 25 at 5:36 AM |
| BidaskClub Downgrades Cara Therapeutics (CARA) to Sell
www.americanbankingnews.com - March 24 at 1:54 PM |
| Cara Therapeutics' (CARA) "Buy" Rating Reaffirmed at Seaport Global Securities
www.americanbankingnews.com - March 22 at 8:12 PM |
| Zacks Investment Research Upgrades Cara Therapeutics (CARA) to Hold
www.americanbankingnews.com - March 21 at 7:16 PM |
| Cramer's lightning round: With so many great bank stocks,...
finance.yahoo.com - March 21 at 5:04 AM |
| Cramer's lightning round: With so many great bank stocks, stay away from Wells Fargo
finance.yahoo.com - March 21 at 5:04 AM |
| Cara Therapeutics (CARA) Given a $22.00 Price Target at HC Wainwright
www.americanbankingnews.com - March 19 at 5:02 PM |
| 3 High-Risk, High-Reward Marijuana Stocks
finance.yahoo.com - March 19 at 3:04 PM |
| Cara Therapeutics Inc (NASDAQ:CARA): When Will It Breakeven?
finance.yahoo.com - March 16 at 3:02 PM |
| Edited Transcript of CARA earnings conference call or presentation 15-Mar-18 8:30pm GMT
finance.yahoo.com - March 16 at 3:02 PM |
| Cara Therapeutics (CARA) Posts Earnings Results, Misses Expectations By $0.04 EPS
www.americanbankingnews.com - March 16 at 9:28 AM |
 | Cara Therapeutics Reports Fourth Quarter and Full Year 2017 ... - GlobeNewswire (press release)
globenewswire.com - March 16 at 5:02 AM |
 | Cara Therapeutics' (CARA) CEO Derek Chalmers on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 16 at 5:02 AM |
 | After-Hours Earnings Report for March 15, 2018 : ADBE, AVGO, ULTA, JBL, OSTK, REV, REI, FSM, GDEN, CBAY ... - Nasdaq
www.nasdaq.com - March 15 at 3:13 PM |
 | Form 4 Cara Therapeutics, Inc. For: Mar 09 Filed by: Terrillion Scott - StreetInsider.com
www.streetinsider.com - March 14 at 3:11 PM |
| Premarket analyst action - healthcare - Cara Therapeutics Inc ... - Seeking Alpha
seekingalpha.com - March 13 at 5:08 AM |
| Cara Therapeutics (CARA) Given a $22.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 12 at 2:25 PM |
| Cara Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018 - GlobeNewswire (press release)
globenewswire.com - March 9 at 5:07 AM |
| Cara Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018
finance.yahoo.com - March 9 at 5:07 AM |
 | Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 1 Trial of ... - PR Newswire (press release)
www.prnewswire.com - March 1 at 3:03 PM |
| Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 1 Trial of Oral KORSUVA™
finance.yahoo.com - March 1 at 3:03 PM |
| Cara Therapeutics Doses First Patient in Phase 1 Trial of Oral KORSUVA™ (CR845/difelikefalin) in Chronic Liver ... - GlobeNewswire (press release)
globenewswire.com - February 28 at 3:13 PM |
| Cara Therapeutics Doses First Patient in Phase 1 Trial of Oral KORSUVA™ (CR845/difelikefalin) in Chronic Liver Disease (CLD) Patients
finance.yahoo.com - February 28 at 3:13 PM |
| Cara Therapeutics Inc (CARA) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - February 28 at 5:36 AM |
| Five Marijuana Stocks to Buy Now
finance.yahoo.com - February 26 at 5:01 AM |
| Cara Therapeutics Inc (CARA) CEO Sells $81,000.00 in Stock
www.americanbankingnews.com - February 21 at 6:46 PM |
| Cara Therapeutics Inc (CARA) SVP Frederique Ph.D. Menzaghi Sells 3,000 Shares
www.americanbankingnews.com - February 20 at 7:32 PM |
| Cara Therapeutics (CARA) & WuXi PharmaTech (Cayman) (WX) Financial Review
www.americanbankingnews.com - February 19 at 3:16 PM |
| Cara Therapeutics (CARA) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - February 13 at 10:48 PM |
| Focused on Two Sectors
finance.yahoo.com - February 13 at 3:07 PM |
 | Marijuana stocks to consider for the long term - Motley Fool
www.fool.com - February 13 at 5:09 AM |
| Cara Therapeutics (CARA) Upgraded to Buy by Janney Montgomery Scott
www.americanbankingnews.com - February 12 at 9:34 PM |
| Forget Amgen -- Cara Therapeutics, Inc. Is a Better Growth Stock ... - Motley Fool
www.fool.com - February 9 at 3:11 PM |
| Cara Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - February 8 at 8:01 AM |
| Cara Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 8:01 AM |
Cara Therapeutics (NASDAQ:CARA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cara Therapeutics (NASDAQ:CARA) Income Statement, Balance Sheet and Cash Flow Statement
Cara Therapeutics (NASDAQ CARA) Stock Chart for Saturday, April, 21, 2018
Loading chart…
